Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxanes plus Cyclophosphamide in Elderly Breast Cancer Patients ≥70 Years
ChiCTR2300069095Phase 4Not yet recruiting
- Sponsor
- Department of Breast Center, West China Hospital of Sichuan University
- Start
- Mar 2023
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of docetaxel and cyclophosphamide in breast cancer (2 arms), sponsored by Department of Breast Center, West China Hospital of Sichuan University. Primary endpoints: Overall survival and Disease-free survival. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
docetaxelcyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2300069095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069095.